Voices From TCT 2015: FDA's Bram Zuckerman On Benefit-Risk Assessments And Approaching FDA Early
This article was originally published in The Gray Sheet
Executive Summary
“The Gray Sheet” talks to FDA cardiovascular device review lead Bram Zuckerman about his decades-long experience at the agency, the future of cardiac devices and why some companies are hesitant about talking to FDA early on about their product development in this podcast interview from the Transcatheter Cardiovascular Therapeutics meeting in San Francisco.
You may also be interested in...
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.